MTX is a standard component of acute GVHD prophylaxis. However, its use can be limited by toxicity. On the basis of disease risk, we prospectively assigned 132 consecutive patients from January 2005 to February 2011 undergoing first allogeneic hematopoietic cell transplant after conditioning with fludarabine and melphalan to acute GVHD prophylaxis with tacrolimus/MTX (TAC/MTX, N ¼ 22), TAC/micro-dose MTX/mycophenolate mofetil (TAC/mMTX/MMF, N ¼ 78) or TAC/MMF (TAC/MMF, N ¼ 32), to optimize acute GVHD prevention and decrease mortality. The median (range) follow-up was 24 (0.8-60) months. The median patient ages (range) were 37 (23-63), 56 (20-68) and 54 (22-68) years (Po0.0001) for TAC/MTX, TAC/mMTX/MMF and TAC/MMF, respectively. The 100-day cumulative incidences of grade III-IV acute GVHD were 19, 23 and 49% (P ¼ 0.015), respectively. The cumulative incidences of severe chronic GVHD at 1 year were 38, 29 and 79% (Po0.001), respectively. Regimen-related toxicities were not significantly different among the three prophylaxis regimens. PFS and OS were equivalent between the TAC/MTX and TAC/mMTX/MMF arms despite significantly older patients in the latter arm, and both had superior PFS and OS than the TAC/MMF arm. Acute GVHD prophylaxis with TAC/mMTX/MMF is as effective as TAC/MTX and superior to TAC/MMF.
INTRODUCTION
Acute GVHD is the major impediment to successful allogeneic hematopoietic cell transplant (alloHCT) and occurs among 35-47% of recipients of related and unrelated allogeneic HLA-matched grafts despite prophylaxis. 1, 2 Starting from single-agent regimens, the combination of tacrolimus (TAC) and MTX has become a standard acute GVHD prophylaxis regimen. [3] [4] [5] [6] However, because of MTX-related toxicities such as liver/kidney abnormalities, delayed neutrophil/platelet engraftment and stomatitis, MTXsparing regimens were developed in an attempt to improve acute GVHD prophylaxis and long-term outcomes. MTX doses were initially reduced without decreased efficacy compared with historical controls. 7 Later, MTX was completely eliminated in regimens using TAC/sirolimus (SIR) as well as TAC/mycophenolate mofetil (MMF). [8] [9] [10] [11] [12] [13] On the basis of disease risk factors, we prospectively assigned alloHCT patients, who received reducedintensity conditioning with fludarabine (FLU) and melphalan (MEL), to acute GVHD prophylaxis with TAC/MTX, TAC/mMTX/ MMF or TAC/MMF with the intent to develop a MTX-sparing prophylaxis regimen to reduce toxicity while maintaining efficacy.
PATIENTS AND METHODS
A total of 132 adult (418 years) alloHCT patients received conditioning with FLU (25 mg/m 2 i.v. on days À 6, À 5, À 4, À 3 and À 2) and MEL (70 mg/m 2 i.v. on days À 3 and À 2) for the treatment of hematologic malignancies from 2005 to 2011 at Roswell Park Cancer Institute (RPCI). 14 Patients received FLU/MEL conditioning if they were not eligible for a myeloablative alloHCT due to disease, HLA mismatch, performance status or prior receipt of an autologous or alloHCT. The clinical protocol for FLU/MEL conditioning was approved by the RPCI institutional review board, and all participants provided written informed consent.
A minimum of 2 Â 10 6 CD34 þ cells/kg (peripheral blood) or 2 Â 10 8 total nucleated cells/kg (BM) were infused. Before 6 January 2008, G-CSF was administered to all patients from day 6 after cell infusion until neutrophil engraftment. Patients with disease-related monosomy 7 cytogenetic abnormalities received GM-CSF instead. Scheduled G-CSF administration was discontinued because of theoretical concerns that it might increase the risk of acute GVHD. 15, 16 On the basis of disease status at transplant, patients were prospectively assigned in a non-randomized manner to a standard (TAC/MTX) or alternative (TAC/mMTX/MMF or TAC/MMF) acute GVHD prophylaxis regimen (Table 1) . Patients at a low risk for disease relapse were assigned to TAC/MTX. Patients at a high and very high risk for disease relapse were assigned to TAC/mMTX/MMF or TAC/MMF. Low risk was defined as ALL or non-Hodgkin lymphoma (NHL)/Hodgkin lymphoma (HL) in CR, AML in CR within 1 month of transplant or myelodysplastic syndrome (MDS) with p10% blasts. High-risk disease was defined as AML in early untreated relapse or with a hypoplastic BM, MDS with 10-20% blasts or secondary etiology or HL/NHL in PR or stable disease after relapse therapy. Very highrisk disease was defined as AML with measurable histopathological disease after reinduction therapy, NHL/HL that progressed/never responded despite therapy (primary induction failure or refractory relapse), ALL not in CR at transplant and AML, ALL, MDS or NHL/HL that relapsed after prior alloHCT. The disease status categories used for assigning acute GVHD prophylaxis were internally derived and partially overlapped with the Center for International Blood and Marrow Transplant Research (CIBMTR) risk categories. 17 Patients were also retrospectively classified according to CIBMTR risk categories as follows: low: AML/ALL in CR1, CML in first chronic phase or CR1, CLL in CRX1, HL/NHL in CR1; MDS RA, RARS, RCMD, RCMD-RS and unclassified or isolated 5q; MM in CR1, VGPR1 and PR1; intermediate: AML/ALL in CRX2, CML in second chronic phase, CR2 or first accelerated phase; CLL in PR, untreated relapse or never treated; HL/ NHL in CRX2, chemo-sensitive relapse or PR1; high: AML/ALL not in remission, CML in third or greater chronic phase, CRX3, second accelerated phase or blast crisis; CLL progression or no response to treatment; HL/NHL not in remission, never treated or less than PR to initial therapy; MDS RAEB-1, RAEB-2 and CMML; MM in CRX2, VGPRX2, PRX2, stable disease, progression and never treated; non-malignant: severe aplastic anemia, Fanconi anemia and Diamond-Blackfan anemia.
All regimens started with a dose of 0.005 mg/kg of TAC i.v. twice daily, with conversion to oral dosing once tolerated. TAC serum concentrations were maintained at 5-10 ng/mL from day À 1 to day 100. TAC/MTX used 10 mg/m 2 
Definitions
Neutrophil engraftment was defined as the first of three consecutive days with an ANC X0.5 Â 10 6 cells/mL. Platelet engraftment was defined as the first day with a platelet count of X20 Â 10 6 platelets/mL without platelet transfusions in the preceding 7 days. Acute GVHD stage and grade were defined according to the Glucksberg criteria, toxicity was graded according to the Bearman criteria and chronic GVHD severity was defined according to the CIBMTR criteria. [18] [19] [20] Acute GVHD organ stage/grade, toxicity data and chronic GVHD (cGvHD) severity grading were prospectively collected. The analysis presented here is retrospective and IRB approved.
Statistical analysis
The Pearson's w 2 -test or Fisher's exact text was used for univariate comparisons of categorical variables. Observation time for acute GVHD was calculated from the date of BMT (day 0) until the date of acute GVHD onset or day þ 100 post BMT and was analyzed as a competing risk with disease progression/relapse or death without GVHD. Observation time for cGVHD was defined as the time from day 0 to cGVHD onset and was analyzed as a competing risk with disease progression/relapse or death without cGVHD. Patients who died before day þ 100 post BMT were excluded from the analysis of cGVHD. Relapse incidence was calculated from day 0 to the date of either relapse (if in CR pre-alloHCT) or progression (if not in CR prealloHCT) and was analyzed as a competing risk with GVHD. OS time was calculated from day 0 to the date of death owing to any cause; patients were censored at the last follow-up. PFS time was calculated from day 0 to the first date of disease progression/relapse or death owing to any cause; patients were censored at the last follow-up in the absence of disease progression/relapse. Kaplan-Meier survival curves were constructed and the difference among the three prophylaxis groups was tested by the logrank statistic. Pairwise comparisons of all outcomes were also performed to test the statistical significance between any two prophylaxis groups. An explanatory Cox proportional hazard model was built for OS, PFS and grade III-IV acute GVHD incorporating the following factors CIBMTR risk a TAC 0.005 mg/kg i.v. bid with later conversion to oral doses maintained at a serum concentration of 5-10 ng/mL from day À 1 to day 100. In the absence of acute GVHD, TAC was tapered by 10% weekly beginning on day 60 (if high-risk disease) with the goal to taper off by day 100 or day 100 with the goal to taper off by day 180 and MMF was discontinued on day 60 without taper. category, HLA-match, age at alloHCT and acute GVHD prophylaxis regimen. All statistical analyses were performed using SPSS version 16 (Chicago, IL, USA) with a two-sided type I error rate of 0.05.
RESULTS

Patient characteristics
Patient characteristics are presented in Table 2 and 11 (3-86) days, respectively. The median (range) times for platelet engraftment were 21 (11-66), 17 (3-92) and 18 (5-36) days, respectively. Neutrophil and platelet engraftment were not significantly different between the three acute GVHD prophylaxis regimens. After 6 January 2008, when routine G-or GM-CSF administration was discontinued, the median (range) times for neutrophil and platelet engraftment for TAC/mMTX/MMF were 17 (10-30) and 19 (10-390) days, respectively. Engraftment times for the TAC/MTX and TAC/MMF prophylaxis regimens could not be calculated owing to small sample sizes (n ¼ 1 and 1).
Acute GVHD The incidence of grade III-IV acute GVHD between the TAC/MTX (19%, 95% CI 2-36%) and TAC/mMTX/MMF (23%, 95% CI 13-33%) groups was not significantly different. In contrast, TAC/MMF (49%, 95% CI 31-67%) resulted in a significantly higher incidence of grade III-IV acute GVHD (P ¼ 0.015) than either MTX-containing regimen (Figure 1a) . Organ-specific involvement by acute GVHD was examined, and a trend toward a higher incidence of stage 2-4 gastrointestinal tract acute GVHD (P ¼ 0.078, Figure 1b) for TAC/ MMF (42%, 95% CI 24-60%) than for TAC/MTX (14%, 95% CI 0-29%) or TAC/mMTX/MMF (23%, 95% CI 13-33%) was observed. Little difference between the three prophylaxis groups was observed in the incidence of stage 2-4 liver or that of stage 3-4 skin acute GVHD. (Figures 1c and d) The incidences of grade IV acute GVHD for TAC/MTX, TAC/mMTX/MMF and TAC/MMF were 9%, 6% and 19%, respectively. Death due to acute GVHD occurred in 5, 3 and 19% by day 100, respectively.
A multivariate analysis to determine the contribution of acute GVHD prophylaxis regimen (TAC/mMTX/MMF vs TAC/MMF), CIBMTR risk category, HLA matching and age to grade III-IV acute GVHD risk was performed (Table 3) . TAC/MTX was not included owing to significant differences in disease status and age, which could confound the analysis. Patients who received TAC/MMF were at a significantly higher risk (HR ¼ 2.36, P ¼ 0.02) for developing grade III-IV acute GVHD than those who received TAC/mMTX/MMF, after controlling for age at alloHCT, HLA match and CIBMTR risk category. As expected, there was a trend toward increased risk of grade III-IV acute GVHD in patients with 7/8 HLAmismatched unrelated donor grafts compared with a 6/6 HLAmatched related or 8/8 HLA-matched unrelated donor grafts. 21 CIBMTR risk and age did not significantly affect grade III-IV acute GVHD risk. The theoretical association between G-or GM-CSF use after alloHCT and acute GVHD was evaluated by examining the incidence of acute GVHD in alloHCTs performed before and after 6 January 2008, the date on which routine, planned growth factor use was discontinued. No significant differences were observed in the incidence of grade III-IV acute GVHD (data not shown).
Sampling bias was evaluated by comparing the proportion of corroborating biopsy samples obtained from the TAC/MTX, TAC/ mMTX/MMF and TAC/MMF groups. Gastrointestinal tract biopsy samples were obtained from 50, 53 and 56% of patients, respectively. Skin biopsy samples were obtained from 45, 42 and 37% of patients, respectively. Only 8% of patients had a liver biopsy. No significant differences in the biopsy rate were observed between the three prophylaxis groups.
Transplant-related toxicities All three regimens were well tolerated. Transplant-related toxicities were not significantly different between the three regimens. The rate of grade II-IV stomatitis was lowest in the TAC/MMF group (16%) compared with the TAC/mMTX/MMF (22%) and TAC/MTX (32%) groups; however, these differences were not statistically significant. The incidences of transplant-related mortality for TAC/MTX, TAC/mMTX/MMF and TAC/MMF were 18%, 10% and 38% at day 100, and 18%, 26% and 59% at 1 year, respectively.
Chronic GVHD The cumulative incidences of severe cGVHD were significantly higher (Po0.0001, Figure 2 ) for TAC/MMF (79%, 95% CI 60-97%) compared with TAC/MTX (38%, 95% CI 13-62%) and TAC/mMTX/ MMF (29%, 95% CI 17-41%). The cumulative incidences of moderate/severe cGVHD at 1 year were 46% (95% CI 20-71%), 45% (95% CI 32-57%) and 95% (95% CI 85-100%), for TAC/MTX, TAC/mMTX/MMF and TAC/MMF, respectively. Death due to cGVHD occurred in 5, 12 and 38% at 1 year in the TAC/MTX, TAC/mMTX/ MMF and TAC/MMF groups, respectively.
Relapse
The incidences of relapse/progression for TAC/MTX, TAC/mMTX/ MMF and TAC/MMF were 21, 11 and o1% at day 100, respectively, and 27, 19 and 9% at 1 year, respectively. PFS and OS When TAC/mMTX/MMF was compared with TAC/MMF, OS was significantly better (P ¼ 0.05) and PFS showed a trend (P ¼ 0.2) toward improvement for TAC/mMTX/MMF (Figures 3a and b) . There was no significant difference between TAC/MTX and TAC/ mMTX/MMF in 1-year OS (64% vs 66%, respectively) or 1-year PFS (59% vs 59%, respectively).
A multivariate analysis of PFS found only CIBMTR intermediate/ high-risk, and HLA mismatch was significantly associated with a lower PFS (Table 3) . GVHD prophylaxis regimen and age were not significantly associated with PFS. The multivariate analysis of OS demonstrated an increased risk of death for patients aged X40 years (HR 3.31, P ¼ 0.05), HLA-mismatched donors (HR 1.93, P ¼ 0.03) and CIBMTR high-risk disease (HR 3.48, Po0.0001), with a minor effect of CIBMTR intermediate-risk disease (HR 2.09, P ¼ 0.08) and FK/MMF (HR 1.62, P ¼ 0.09) on the mortality risk (Table 3) . DISCUSSION TAC/mMTX/MMF is as effective as TAC/MTX for acute GVHD prophylaxis in patients conditioned with FLU/MEL receiving an alloHCT. Both regimens are superior to TAC/MMF; thus, we were unable to confirm the adequacy of TAC/MMF for GVHD prophylaxis. [11] [12] [13] We observed a higher incidence of grade III-IV acute GVHD for all three prophylaxis regimens than previously reported by other groups. [11] [12] [13] 22, 23 These differences were likely due to older patient age and higher percentage of HLA-mismatched transplants and CIBMTR high-risk patients in our cohort. Despite this, our PFS and OS estimates are comparable to previous reports. [24] [25] [26] One trend in acute GVHD prophylaxis has been to reduce or eliminate the dose of MTX. TAC/SIR has been tested as a MTXsparing acute GVHD prophylaxis regimen in reduced intensity alloHCT using matched related donors. 27, 28 TAC/SIR has only been studied in HLA-matched siblings with a low-risk disease who received different conditioning regimens and graft sources than our cohort.
We suggest that TAC/mMTX/MMF may be an alternative to SIRbased acute GVHD prophylaxis regimens because it does not require SIR-level monitoring, has fewer interactions with azole drugs and has less pneumonitis. 29 BMT CTN 0402, a phase-3 randomized trial comparing acute GVHD prophylaxis with TAC/ MTX versus TAC/SIR, in a preliminary report showed no significant differences between the two regimens. 30 The superiority of TAC/MTX and TAC/mMTX/MMF over TAC/MMF acute GVHD prophylaxis may be explained by the differential pharmacology of MTX and MMF. T and B cells do not use the salvage pathway for purine synthesis but rely upon de novo synthesis, and MMF is an inhibitor of IMP dehydrogenase, an enzyme crucial to de novo purine nucleotide synthesis. 31, 32 Therefore, MMF's effects are specific to T and B lymphocytes. 33 MTX nonspecifically inhibits cellular proliferation by antagonizing folate metabolism. 34 During acute GVHD development, MTX may inhibit the spectrum of immunologically active cells. This broader inhibition of the immune response may have resulted in our lower observed incidence of acute GVHD and longer OS in the MTXcontaining prophylaxis arms.
The strength of this study is that it compares three prospectively assigned acute GVHD prophylaxis regimens using different doses of MTX after a standard reduced-intensity conditioning regimen. Although the TAC/mMTX/MMF group included older patients at higher risk for acute GVHD and poor transplant outcomes compared with the TAC/MTX group, the incidences of acute and cGVHD, OS and PFS were equivalent between these two regimens. Thus, TAC/mMTX/MMF may be a superior acute GVHD prophylaxis regimen. A limitation of this study is a possible cohort effect due to the enrollment of patients treated with TAC/mMTX/ MMF and TAC/MMF in sequential cohorts. However, the characteristics of patients in the TAC/MMF and TAC/mMTX/MMF groups, including relative proportions of high-and low-CIBMTRrisk patients and an older patient age, did not significantly differ, and we did not find evidence of a cohort effect in sensitivity and subgroup analyses (data not shown), grade III-IV acute GVHD incidence, OS and PFS. These data indicate an advantage for patients receiving acute GVHD prophylaxis with TAC/mMTX/MMF compared with TAC/MMF.
In summary, we observe that TAC/mMTX/MMF is as effective as TAC/MTX and superior to TAC/MMF for acute GVHD prophylaxis. Although improved toxicity or engraftment was not seen in the TAC/mMTX/MMF arm compared with the TAC/MTX arm, the observation of an equivalent incidence of acute and cGVHD, PFS and OS in a higher-risk population suggests that TAC/mMTX/MMF may be superior to TAC/MTX and acceptable acute GVHD prophylaxis. These data challenge the paradigm of completely eliminating MTX from acute GVHD prophylaxis regimens to improve tolerability while maintaining efficacy. Dose reduction of MTX in combination with MMF is another strategy that may result in improved outcomes. 
